Vectus Biosystems (ASX: $VBS) March 2024 Quarterly Activities Report

Vectus Biosystems Limited (ASX: $VBS) has released its March 2024 Quarterly Activities Report and Quarterly Cash Flow Report - Appendix 4C. The company announced the closure of recruitment for the current Phase lb human clinical trial, allowing for the opening of the code and the assessment of potential biomarkers. Vectus also provided updates on its research and development (R&D) activities, financial position, and corporate strategy.

Executive Commentary on March 2024 Quarter Activities

Vectus announced the completion of recruitment for the Phase lb human clinical trial, marking a significant milestone in the development of its lead compound, VB0004. The availability of the complete data set enables the assessment of potential biomarkers, and the company plans to report these results in due course. Additionally, Vectus is focused on generating additional data on VB0004 and progressing two other candidates, A32 and A79. The company continues to target potential partners and licensees in the fibrosis market, aiming to advance its leads towards commercialization. Financially, Vectus expended funds on finalizing the Phase la clinical trials for VB0004 and the Phase lb work, with cash-on-hand at $1,367,000 as of 31 March 2024. The company also received R&D refunds from the Australian Taxation Office and is actively evaluating options to address its future capital requirements.

Summary of Vectus Biosystems March 2024 Quarterly Activities

Vectus Biosystems (ASX: $VBS) announced the closure of recruitment for the Phase lb human clinical trial, allowing for the assessment of potential biomarkers. The company is focused on generating additional data on VB0004 and progressing two other candidates, A32 and A79, while expanding its outreach and licensing program. Vectus continues to target potential partners and licensees in the fibrosis market and is actively evaluating options to address its future capital requirements. With cash-on-hand at $1,367,000 as of 31 March 2024 and expected R&D refunds, the company aims to continue its operations and meet its business objectives based on positive discussions with potential trade partners.